Proteins that work.
When it comes to vaccines and monoclonal antibodies there’s typically a trade-off is between performance and speed-to-market. Boost delivers high-performance proteins at the speed of mRNA. We create safe and effective vaccine antigens and monoclonal antibodies that work in the lab, clinic, and market.
Our proteins are designed to perform…
>>> In the Lab <<<
Boost’s protein engineering expertise and proprietary Rapid Antigen Deployment (RAD™) frameworks allow us to quickly create and update antigens that are used in vaccines, and for the generation of monoclonal antibodies. Notably, Boost’s antigens are unique and designed for stability, purity, producibility, immunogenicity, and neutralization. Our data proves our capabilities.
>>> In the Clinic <<<
Based on extensive preclinical studies, and support from NIH/NIAD and CEPI, Boost is has started Phase 1 clinical trials for a RAD™-enabled SARS-CoV-2 antigen that is being evaluated as an adjuvanted intramuscular injection, 100% adjuvant-free intramuscular injection, and 100% adjuvant-free nasal spray. Data from these Phase 1 clinical studies will be available by mid-2026.
>>> In the Market <<<
Boost has deep experience optimizing and scaling protein production. Our antigens and monoclonal antibodies enable relatively low-cost production – above and beyond their clinical performance characteristics. Our approach to regulatory strategy and implementation, and intellectual property protection, reduces risk and is designed to ensure commercial success.
Backed by the Best
Boost benefits from financial support, preclinical services, and clinical services from two of the world's leading organizations that support human health and biotechnology innovation.
The company is also supported by a group of dedicated and knowledgable investors.
One platform, many pathogens
Here’s how we do it:
A pathogen-specific RAD™ framework is created: Custom-built for each threat
Scale-up ready antigens can be deployed in as little as 10 days: Made in advance or on demand
Rapid therapeutics, diagnostics & vaccines are possible: Time-to-market can be dramatically shortened
Let’s discuss opportunities.
If you're an investor, partner, or collaborator who shares our vision of a company that is being built to respond to health crises with safety, efficacy, speed, and cost in mind, we want to hear from you.